541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4(+) Count, and WHO Clinical Staging

BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen approved in Europe and under regulatory review in the United States for the treatment of HIV-1 infection. In the pivotal AMBER trial in antiretroviral treatment (...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinner, Christoph D, Rashbaum, Bruce, Mcdonald, Cheryl, Mussini, Cristina, Luo, Donghan, Jezorwski, John, Brown, Kimberley, Wong, Eric Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253519/
http://dx.doi.org/10.1093/ofid/ofy210.550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253519/
http://dx.doi.org/10.1093/ofid/ofy210.550

Ejemplares similares